Inequity in access to guideline-recommended colorectal cancer treatment in Nova Scotia, Canada

Similar documents
Reaping the Benefits of Cancer Registries: Examples from End of Life Studies

SCHOOL-BASED IMMUNIZATION COVERAGE IN NOVA SCOTIA:

DIABETES CARE PROGRAM OF NOVA SCOTIA NOVA SCOTIA DIABETES STATISTICS REPORT

End of Life Care in Nova Scotia: Surveillance Report. Dr. Fred Burge June 13, 2008

d i a b e t e s care program of nova scotia Nova Scotia diabetes

INFLUENZA Surveillance Report Influenza Season

Quality indicators for end of life care:

Seniors Falls in Nova Scotia A REPORT

Palliative Care Program Data in Nova Scotia

INEQUITY IN ACCESS TO COLORECTAL CANCER SERVICES ALONG THE CONINTUUM OF CARE IN NOVA SCOTIA. André R. Maddison

Financial Disclosure. Team. Race-based Socioeconomic and Treatment Disparities in Adolescents and Young Adults with Stage II-III Rectal Cancer

Palliative Care Program Data in District Health Authorities 1 to 7 in Nova Scotia

Building Interdisciplinary Research Capacity in End of Life Care

A Population-Based Study on the Uptake and Utilization of Stereotactic Radiosurgery (SRS) for Brain Metastasis in Nova Scotia

On-going and planned colorectal cancer clinical outcome analyses

Physician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer

Predictors of Palliative Therapy Receipt in Stage IV Colorectal Cancer

End of Life Care in Nova Scotia Surveillance Report

Time intervals for isolated care steps in the diagnosis

The effect of surgeon volume on procedure selection in non-small cell lung cancer surgeries. Dr. Christian Finley MD MPH FRCSC McMaster University

Estimates and predictors of health care costs of esophageal adenocarcinoma: a population-based cohort study

PROCARE FINAL FEEDBACK

Introduction to the POWER Study Chapter 1

Impact of deprivation and rural residence on treatment of colorectal and lung cancer

NOVA SCOTIA RECTAL CANCER PROJECT: A POPULATION-BASED ASSESSMENT OF RECTAL CANCER CARE AND OUTCOMES. Devon Paula Richardson

Physician Resource Plan and Physician Employment

The New CP 3 R Application And Revisions To Standard 4.6 Integration Of The NCDB With The Accreditation Process

Provider Contribution to Overuse and Underuse of Colorectal Cancer Screening (mostly colonoscopy)

Trends and disparities in cancer in Aotearoa/ NZ

Cancer System Quality Index th Annual Launch Event

National Bowel Cancer Audit Supplementary Report 2011

Canada: Equitable Cancer Care Access and Outcomes? Historic Observational Evidence: Incidence Versus Survival, Canada Versus the United States

EXECUTIVE DIRECTOR S MESSAGE

Outcomes of Patients with Preoperative Weight Loss following Colorectal Surgery

What were the key findings from the routinely-collected data?

Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer

End-of-Life Care in Nova Scotia: Opportunities for Improvement

Colorectal Cancer at the MemorialCare Todd Cancer Institute at Long Beach Memorial

6/20/2012. Co-authors. Background. Sociodemographic Predictors of Non-Receipt of Guidelines-Concordant Chemotherapy. Age 70 Years

Factors associated with delayed time to adjuvant chemotherapy in stage iii colon cancer

CERCIT Project 2: Assessing the Quality of Cancer Treatment in Texas. Sharon Giordano

Ian Landry, MPH Beth Schmidt, MSPH

DIABETES MORTALITY IN NOVA SCOTIA FROM 1998 TO 2005: A DESCRIPTIVE ANALYSIS USING BOTH UNDERLYING AND MULTIPLE CAUSES OF DEATH

Surveillance of Pancreatic Cancer Patients Following Surgical Resection

ANNUAL REPORT. Figure 2 displays the distribution of the number of these diagnoses in 2013 by age (along the X axis) and by gender.

South West Regional Cancer Program. Cancer Plan

Surgical Outcomes: A synopsis & commentary on the Cardiac Care Quality Indicators Report. May 2018

Cancer. It s about all of us. ACP/GOC CPAC Project: Nova Scotia and Manitoba. Canadian Hospice Palliative Care Association

Factors Associated with Initial Treatment for Clinically Localized Prostate Cancer

NOTIFIABLE DISEASES IN NOVA SCOTIA 2011 SURVEILLANCE REPORT. Population Health Assessment and Surveillance

DAYS IN PANCREATIC CANCER

ADJUVANT CHEMOTHERAPY...

Do rural cancer patients present later than those in the city?

Is distance to chemotherapy an obstacle to adjuvant care among the N.C. Medicaid enrolled colon cancer patients?

Colorectal cancer incidence in Aboriginal Ontarians: a cautionary ecologic tale

Utilization of OncoType DX Test for

The poor cancer patient - social inequality in outcomes after cancer

WHAT FACTORS INFLUENCE AN ANALYSIS OF HOSPITALIZATIONS AMONG DYING CANCER PATIENTS? AGGRESSIVE END-OF-LIFE CANCER CARE. Deesha Patel May 11, 2011

Patterns of cancer centre follow-up care for survivors of breast, colorectal, gynecologic, and prostate cancer

PATTERN OF DIABETES THERAPEUTIC PRESCRIPTION IN RURAL AND URBAN AREAS IN QUEBEC

Treatment disparities among elderly colon cancer patients in the United States using SEER-Medicare data

Care at the End of Life among People Living With HIV in Ontario

Manchester Cancer Colorectal Pathway Board: Guidelines for management of colorectal hepatic metastases

RECTAL CANCER APPARENT COMPLETE RESPONSE (acr) AFTER LONG COURSE CHEMORADIOTHERAPY

Patterns of health care utilization preceding a colorectal cancer diagnosis are strong predictors of dying quickly following diagnosis

Measuring health care inequalities using the Census- DAD data linkage

Patient and Hospital Characteristics Associated with Nephron-Sparing Surgery for Small, Localized Kidney Cancers in California,

Colorectal Cancer in Idaho November 2, 2006 Chris Johnson, CDRI

SOCIOECONOMIC PREDICTORS OF SHORT DIAGNOSIS TO DEATH FOLLOWING COLORECTAL CANCER DIAGNOSIS: A POPULATION-BASED STUDY USING RECURSIVE PARTITIONING

COLORECTAL CARCINOMA

Access to Health Services in Urban and Rural Australia: a Level Playing Field?

Trends and Comparative Effectiveness in Treatment of Stage IV Colorectal Adenocarcinoma

Influence of Lymphadenectomy on Survival for Early-Stage Endometrial Cancer

UNIVERSITY OF CALGARY. diabetes mellitus. Vinay Deved A THESIS SUBMITTED TO THE FACULTY OF GRADUATE STUDIES

Department of Epidemiology, University of Iowa College of Public Health, Iowa City, IA, 2. College of Medicine, Iowa City, I

Colorectal Cancer. Mark Chapman. MA MS FRCS EBSQ(coloproct) 21 st March 2018 Consultant Coloproctologist

Effect of post-intubation hypotension on outcomes in major trauma patients

Treatment of Locally Advanced Rectal Cancer: Current Concepts

Equity, Poverty, and Access Canada

The Burden of Kidney Disease in Rural & Northern Ontario

Mediation of the effects of living in extremely poor neighborhoods by health insurance: breast cancer care and survival in California, 1996 to 2011

What do the new evolutions in GI cancer mean for my practices

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Endoscopic ultrasound and impact on survival in rectal cancer patients : a SEER-Medicare study.

Debate: General surveillance/screening for colon cancer in a resource constrained environment is imperative

Outcome following surgery for colorectal cancer

!"#$ Oncology Outcomes Report

THE SURVIVAL BENEFITS OF

PHARMO Database Network

Shore Medical Center Site-Specific Study: Colorectal Cancer 2013

Towards Understanding

The Current Landscape of Nurse Navigators: Oncology and the Impact on Outcomes

2016 Cancer Annual Report. Using data from 2015

Cancer prevention and control

Rural and urban differences in stage at diagnosis of colorectal and lung cancers

Cardiovascular. Mathew Mercuri PhD(C), Sonia S Anand MD PhD FRCP(C)

Burden of Illness. Chapter 3 -- Highlights Document ONTARIO WOMEN'S HEALTH EQUITY REPORT

C3: Cancer, Care and Comorbidity

Outcome of rectal cancer after radiotherapy with a long or short waiting period before surgery, a descriptive clinical study

Palliative radiotherapy utilization for cancer patients at end of life in British Columbia: retrospective cohort study

Transcription:

Inequity in access to guideline-recommended colorectal cancer treatment in Nova Scotia, Canada André Maddison MSc, Yukiko Asada PhD, Robin Urquhart PhD(c), Grace Johnston PhD, Fred Burge MD MSc CAHSPR Conference May 11, 2011

Colorectal cancer (CRC) care continuum CRC care Screening Diagnosis Preoperativoperative Surgery Post- therapy therapy Follow-up care

Colorectal cancer All physician and hospital services covered under the provincial funding plans However. Lower income associated with longer wait times (Winger et al 2008) Rural residency associated with longer wait times (Singh et al. 2010) Older individuals half as likely to receive treatment (Cree et al. 2009)

Observations from the current literature (1): Inequality vs. inequity Inequality: variations in access (every individual does not have identical access) Inequity: variations in access that are ethically problematic Identification of inequity Variations due to need factors: equitable Variations due to non-need factors, after adjustment for need factors: inequitable

Observations from the current literature (2): Inequality indices Yet to take advantage of inequality indices Concentration Index Increasingly used for population-level equity studies Makes comparison easy between studies, points of service, and over time

Study objectives 1. To clearly define inequity in access to CRC care by adjusting for clinical practice guidelines and patient need for care 2. To calculate the degrees of income-, age-, sex-, and distance-related inequities in access to chemotherapy and radiotherapy for patients diagnosed CRC in Nova Scotia

Data ACCESS Cohort Nova Scotia Cancer Registry identified all individuals diagnosed with CRC between 01/01/2001 31/12/2005 Linked to 14 administrative databases, including: Oncology Patient Information System Hospital Discharge Abstracts Physician billings Capital Health and Cape Breton palliative care data 2001 Census of Canada

Study population individuals who were diagnosed with: stage II or III rectal cancer or stage III colon cancer, and who underwent surgical resection of their tumour n=1094

Dependent variables 1. Receipt of chemotherapy and/or radiotherapy according to Canadian clinical practice guidelines (yes/no) Stage III colon cancer (Figueredo et al. 2003) Adjuvant chemotherapy Stage II/III rectal cancer (Figueredo et al. (2004) Adjuvant chemotherapy Neo-adjuvant or adjuvant radiotherapy 2. Wait time from radiation oncology referral to consultation within 14 days (yes/no)

Independent variables Need variables: Non-need variables Previous cancer diagnosis No, Yes Co-morbid conditions 0, 1, 2+ Income ($) <30,000, 30,000-44,999, 45,000+ Distance to the nearest cancer centre (Km) Sex 0-14.99, 15-74.99, 75-124.99, 125+ M, F Age at diagnosis (years) <60, 60-69, 70-79, 80+ Disease site Tumour stage Colon, rectal II, III Year of diagnosis 2001, 2002, 2003, 2004, 2005 Region of Nova Scotia (1) CDHA, (2) CBDHA, (3) Annapolis valley, S. Shore, and S.W. Shore, (4) Colchester East Hants, Pictou county and Guysborough Antigonish strait

Measure of inequity The Concentration Index A measure of variation Always measures variation of access by X (e.g., income) Index values between -1 and 1 Inequitable variations Variations after adjustment for need i.e., removing the influence of need

Analysis 1. Model observed use according to guidelines 2. Estimate need expected use according to guidelines 3. Calculate guideline-need-standardized use

1. Model observed use according to guidelines Run logistic regression models to identify factors that were associated with observed health care use according to clinical practice guidelines Observed use according to guidelines Factor 1 Factor 2 Factor 3

2. Estimate need expected use according to guidelines Observed use according to guidelines Factor 1 Factor 2 Factor 3 Distinguish factors into need and non-need Observed use according to guidelines Need factors Non-need factors Ethically justifiable or socially unproblematic Ethically unjustifiable

2. Estimate need-expected use according to guidelines Purge the influence of non-need factors, and predict needexpected use based only on need factors Need expected use according to guidelines Need factors Non-need factors Holding constant

3. Calculate guideline-needstandardized use Guideline-needstandardized use Observed use according to guidelines Need expected use according to guidelines Population mean

Key descriptive results Radiotherapy variables n (1094) % Disease site Colon 591 54.0 Rectum 504 46.0 Age at diagnosis <60 277 25.2 60-69 265 24.2 70-79 316 28.9 80+ 236 21.6 Sex Men 605 55.3 Women 489 44.7 Co-morbidities 0 670 61.2 1 207 18.9 2+ 217 19.9

Key descriptive results Radiotherapy variables n (1094) % Disease site Colon 591 54.0 Rectum 504 46.0 Age at diagnosis <60 277 25.2 60-69 265 24.2 70-79 316 28.9 80+ 236 21.6 Sex Men 605 55.3 Women 489 44.7 Co-morbidities 0 670 61.2 1 207 18.9 2+ 217 19.9

Key descriptive results Radiotherapy variables n (1094) % Disease site Colon 591 54.0 Rectum 504 46.0 Age at diagnosis <60 277 25.2 60-69 265 24.2 70-79 316 28.9 80+ 236 21.6 Sex Men 605 55.3 Women 489 44.7 Co-morbidities 0 670 61.2 1 207 18.9 2+ 217 19.9

Key descriptive results Radiotherapy variables n (1094) % Disease site Colon 591 54.0 Rectum 504 46.0 Age at diagnosis <60 277 25.2 60-69 265 24.2 70-79 316 28.9 80+ 236 21.6 Sex Men 605 55.3 Women 489 44.7 Co-morbidities 0 670 61.2 1 207 18.9 2+ 217 19.9

Key descriptive results Radiotherapy variables n (1094) % Disease site Colon 591 54.0 Rectum 504 46.0 Age at diagnosis <60 277 25.2 60-69 265 24.2 70-79 316 28.9 80+ 236 21.6 Sex Men 605 55.3 Women 489 44.7 Co-morbidities 0 670 61.2 1 207 18.9 2+ 217 19.9

Results Key adjusted Odds Ratios (OR) Use according to guidelines Receipt of clinically recommended treatment Wait time from radiation oncology referral to consultation within 14 days OR (95% CI) OR (95% CI) Age at diagnosis <60 1.0 1.0 60-69 0.64 (0.42, 0.97) 70-79 0.20 (0.13, 0.30) 80+ 0.022 (0.01, 0.04) Sex Male 1.0 1.0 Distance to the nearest cancer centre (KMs) Female 0.61 (0.45, 0.83) 0-14.99 1.00 15-74.99 0.74 (0.47, 1.16) 75-124.99 0.63 (0.34, 1.18) 125+ 0.46 (0.24, 0.89) 0.95 (0.36, 2.51) 0.72 (0.27, 1.87) 0.92 (0.36, 2.36) 0.91 (0.55, 1.50) 1.00 1.14 (0.57, 2.27) 0.97 (0.36, 2.59) 0.89 (0.30, 1.90)

Results Key adjusted Odds ratios (OR) Use according to guidelines Receipt of clinically recommended treatment Wait time from radiation oncology referral to consultation within 14 days OR (95% CI) OR (95% CI) Age at diagnosis <60 1.0 1.0 60-69 0.64 (0.42, 0.97) 70-79 0.20 (0.13, 0.30) 80+ 0.022 (0.01, 0.04) Sex Male 1.0 1.0 Distance to the nearest cancer centre (KMs) Female 0.61 (0.45, 0.83) 0-14.99 1.00 15-74.99 0.74 (0.47, 1.16) 75-124.99 0.63 (0.34, 1.18) 125+ 0.46 (0.24, 0.89) 0.95 (0.36, 2.51) 0.72 (0.27, 1.87) 0.92 (0.36, 2.36) 0.91 (0.55, 1.50) 1.00 1.14 (0.57, 2.27) 0.97 (0.36, 2.59) 0.89 (0.30, 1.90)

Results Key adjusted Odds ratios (OR) Use according to guidelines Receipt of clinically recommended treatment Wait time from radiation oncology referral to consultation within 14 days OR (95% CI) OR (95% CI) Age at diagnosis <60 1.0 1.0 60-69 0.64 (0.42, 0.97) 70-79 0.20 (0.13, 0.30) 80+ 0.022 (0.01, 0.04) Sex Male 1.0 1.0 Distance to the nearest cancer centre (KMs) Female 0.61 (0.45, 0.83) 0-14.99 1.00 15-74.99 0.74 (0.47, 1.16) 75-124.99 0.63 (0.34, 1.18) 125+ 0.46 (0.24, 0.89) 0.95 (0.36, 2.51) 0.72 (0.27, 1.87) 0.92 (0.36, 2.36) 0.91 (0.55, 1.50) 1.00 1.14 (0.57, 2.27) 0.97 (0.36, 2.59) 0.89 (0.30, 1.90)

Results Key adjusted Odds ratios (OR) Use according to guidelines Receipt of clinically recommended treatment Wait time from radiation oncology referral to consultation within 14 days OR (95% CI) OR (95% CI) Age at diagnosis <60 1.0 1.0 60-69 0.64 (0.42, 0.97) 70-79 0.20 (0.13, 0.30) 80+ 0.022 (0.01, 0.04) Sex Male 1.0 1.0 Distance to the nearest cancer centre (KMs) Female 0.61 (0.45, 0.83) 0-14.99 1.00 15-74.99 0.74 (0.47, 1.16) 75-124.99 0.63 (0.34, 1.18) 125+ 0.46 (0.24, 0.89) 0.95 (0.36, 2.51) 0.72 (0.27, 1.87) 0.92 (0.36, 2.36) 0.91 (0.55, 1.50) 1.00 1.14 (0.57, 2.27) 0.97 (0.36, 2.59) 0.89 (0.30, 1.90)

Inequity in access to CRC care 0.25 Receipt of clinically recommended treatment Wait times Specialist use Allin S, 2008 Concentration Index 0.2 0.15 0.1 0.05 Pro-advantaged Pro-rich Pro-young Pro-male Pro-close 0-0.05 Income Age Sex Distance Pro-disadvantaged

Inequity in access to CRC care 0.25 Receipt of clinically recommended treatment Wait times Specialist use Allin S, 2008 Concentration Index 0.2 0.15 0.1 0.05 Pro-advantaged Pro-rich Pro-young Pro-male Pro-close 0-0.05 Income Age Sex Distance Pro-disadvantaged

Inequity in access to CRC care 0.25 Receipt of clinically recommended treatment Wait times Specialist use Allin S, 2008 Concentration Index 0.2 0.15 0.1 0.05 Pro-advantaged Pro-rich Pro-young Pro-male Pro-close 0-0.05 Income Age Sex Distance Pro-disadvantaged

Inequity in access to CRC care 0.25 Receipt of clinically recommended treatment Wait times Specialist use Allin S, 2008 Concentration Index 0.2 0.15 0.1 0.05 Pro-advantaged Pro-rich Pro-young Pro-male Pro-close 0-0.05 Income Age Sex Distance Pro-disadvantaged

Inequity in access to CRC care 0.25 Receipt of clinically recommended treatment Wait times Specialist use Allin S, 2008 Concentration Index 0.2 0.15 0.1 0.05 Pro-advantaged Pro-rich Pro-young Pro-male Pro-close 0-0.05 Income Age Sex Distance Pro-disadvantaged

Summary of results Indications of pro-young, pro-male, and pro-close distance inequity in receipt of treatment for CRC in Nova Scotia No statistically significant inequity in wait times for services based on income, age, sex, or distance Age-related inequity is of greatest concern

Strengths Limitations Application of the need-standardization approach for clinical data and its expansion with the use of clinical practice guidelines Tumour stage and comorbidity data to approximate patient need for care Need vs. Non-need factors No gold standard Crude co-morbidity measure Inability to capture patient choice

Take home messages For cancer researchers It is important to clearly distinguish inequity from inequality The use of need-standardization methods will enhance comparability of results For policy-makers Even with universal health insurance and clinical guidelines, some CRC care may be inequitable

Contact information André Maddison MSc, MD Candidate 2014 Faculty of Medicine, Dalhousie University andre.maddison@dal.ca

Inequity in access to CRC care Receipt of clinically recommended treatment Radiation oncology wait times Equity stratifier Concentration index (95% Confidence interval) Income 0.01 (-0.02, 0.04) 0.00 (-0.06, 0.06) Age 0.22 (0.19, 0.25) -0.01 (-0.07, 0.05) Sex 0.05 (0.02, 0.08) 0.02 (-0.04, 0.08) Distance 0.05 (0.02, 0.09) 0.05 (-0.01, 0.11)

Ease of comparability by Inequality index Example: Inequality in access to care Study 1 Odds ratio Study 2 Odds ratio Poor 1.00 $ <25,000 1.00 Middle 1.2 $ 25,000-49,999 1.3 Rich 2.0 $ 50,000-74,999 1.5 Income-related inequality Concentration Index $ 75,000-99,999 1.9 $ >100,000 2.1 0.1 0.3 Concentration Index

Concentration Index % share health care acces SES SES

Equity stratifiers and interpretation of the Concentration Index Equity stratifier Better access for: Disadvantaged Advantaged -1 Concentration Index <0 0> Concentration Index 1 Income Poor Rich Age Old Young Sex Women Men Distance Far Close Inequity